StockData
GRI Bio, Inc. logo

GRI Bio, Inc. (GRI) stock

GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.12+0.00 (0.00%)

Close on Nov 20, 2026Market cap $2.45MP/E –Yield –

GRI Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

GRI Bio's free cash flow for the twelve months ending Dec 31, 2024 was -$8.61M. For fiscal 2025 it was -$10.19M. The highest annual figure on record is -$1.09M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.19M–
FY2024Dec 31, 2024-$8.61M–
FY2023Dec 31, 2023-$9.00M–
FY2022Dec 31, 2022-$1.09M–
FY2021Dec 31, 2021-$8.31M–
FY2020Dec 31, 2020-$3.71M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$2.00M–
Q3 FY2024Sep 30, 2024-$2.27M–
Q4 FY2023Dec 31, 2023-$5.56M–
Q3 FY2023Sep 30, 2023-$1.31M–
Q4 FY2022Dec 31, 2022-$847.00K–
Q3 FY2022Sep 30, 2022-$125.00K–
Q4 FY2021Dec 31, 2021-$1.58M–
Q3 FY2021Sep 30, 2021-$1.29M–
Q4 FY2020Dec 31, 2020-$808.00K–
Q3 FY2020Sep 30, 2020-$1.06M–
Q2 FY2020Jun 30, 2020-$1.07M–
Q1 FY2020Mar 31, 2020-$768.00K–

More GRI Bio figures

See a number that looks wrong?